Brucella L7/L12 protein antigen epitope polypeptides and application thereof

Abstract

The invention discloses brucella L7 / L12 protein antigen epitope polypeptides and an application thereof. The polypeptides comprise a polypeptide having an amino acid sequence containing SEQ ID NO.1 or a sequence shown in the SEQ ID NO:1 and formed by substitution and / or deletion of one or / and a plurality of amino acid residues, and also can be a derivative polypeptide having the amino acid sequence being a sequence shown in the SEQ ID NO:1 and having addition of a brucella immunogenicity function. A recombinant vector or expression cassette or transgenic cell or recombinant bacteria can be composed of the SEQIDNO.1 polypeptides. The application of the polypeptides in preparation of reagents or drugs for diagnosis or prevention or treatment of diseases caused by brucella is provided. The screening polypeptides are chemically synthesized; after DC stimulation, high-concentration IL-4 can be released and can be used as a target antigen for detection of serum infected by brucella, or an antigen for preparation of an L7 / L12 protein monoclonal antibody.

Description

technical field [0001] The invention relates to a polypeptide, in particular to a Brucella L7 / L12 protein antigen epitope polypeptide and application thereof. Background technique [0002] Brucella, a Gram-negative facultative intracellular parasite, is a serious zoonotic disease that widely infects domestic animals, wild animals and humans. Brucella in domestic animal animals mainly infects sheep, cattle and pigs Among them, the main ones that are pathogenic to humans are Brucella malta and Brucella abortus; Brucellosis infecting domestic animals causes epididymitis in male animals and abortion, placental inflammation and infertility in pregnant animals; for humans, Brucella Bacteroidosis causes acute inflammation and many symptoms similar to influenza infection, including wave fever, sweating, back pain, and weakness. In some patients, acute clinical symptoms can last for more than a year and eventually lead to chronic persistent infection. Clinical symptoms include irreg...

AI Technical Summary

Problems solved by technology

[0003] At present, the effective vaccines used to prevent brucellosis all over the world are attenuated live vaccines. The use of various vaccines not only interferes with the differential diagnosis of vaccine immunity and natural infection, but also all vaccine strains are harmful to humans to varying degrees. Virus-causing, even some vaccines are highly pathogenic to humans, and the research effect of safe and reliable inactivated vaccines is poor, and they cannot play an immune protection role

The study of genetically engineered vaccines has been concerned and worked hard by researchers all over the world in recent decades. However, due to the diversity and complex structure of Brucella's immune antigens, vaccine antigens that can be used in field trials have not been found. It is an effective way to solve this problem by developing a subunit vaccine with high preventive protection.

[0004] Most of the expression tools in the prior art can only express one protein, while Brucella has a variety of immune-related proteins. Studies have shown that the expression of a single protein cannot form an effective protective vaccine antigen, and multiple prevention and control vaccines can be prepared by expression The cost of the subunit vaccine is high, and the composition is complex; while the component that determines the function of the immune protein is a tiny epitope located on the protein. The mining and identification of the immune epitope of the immune-related protein can effectively extract the brucellosis Effective immune antigen components in bacteria, and also provide direct guidance for protein structure and function research, the determination of epitope antigen components can provide good antigen components for detection, prevention or treatment

Images